Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia
| Autor: | Aditya Mehta, Prakash Vishnu, Asher Chanan-Khan, Rami Manochakian, Suman Biswas, Aneel Paulus, Taimur Sher, Leyla Bojanini, Julian A. Marin-Acevedo, Sonikpreet Aulakh, Sikander Ailawadhi, Victoria R. Alegria, Meghna Ailawadhi, Vivek Roy, Madiha Iqbal, Winston Tan, Vivek Kumar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Risk medicine.medical_specialty Chronic lymphocytic leukaemia Multivariate analysis Adolescent Chronic lymphocytic leukemia Population lcsh:RC254-282 Article Young Adult Cancer Survivors Survivorship curve Internal medicine Epidemiology medicine Humans Young adult education Aged Aged 80 and over education.field_of_study business.industry Neoplasms Second Primary Hematology Middle Aged medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Leukemia Lymphocytic Chronic B-Cell United States Leukemia Standardized mortality ratio Oncology Risk factors Multivariate Analysis Female business SEER Program |
| Zdroj: | Blood Cancer Journal, Vol 9, Iss 10, Pp 1-10 (2019) Blood Cancer Journal |
| ISSN: | 2044-5385 |
| Popis: | With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences in risk for SPMs among CLL survivors from the Surveillance, Epidemiology, and End Results (SEER) database (1973–2015) were compared to risk of individual malignancies expected in the general population. In ~270,000 person-year follow-up, 6487 new SPMs were diagnosed with a standardized incidence ratio (SIR) of 1.2 (95% CI:1.17–1.23). The higher risk was for both solid (SIR 1.15; 95% CI:1.12–1.18) and hematological malignancies (SIR 1.61; 95% CI:1.5–1.73). The highest risk for SPMs was noted between 2 and 5 months after CLL diagnosis (SIR 1.57; 95% CI:1.41–1.74) and for CLL patients between 50- and 79-years-old. There was a significant increase in SPMs in years 2003–2015 (SIR 1.36; 95% CI:1.3–1.42) as compared to 1973–1982 (SIR 1.19; 95% CI:1.12–1.26). The risk of SPMs was higher in CLL patients who had received prior chemotherapy (SIR 1.38 95% CI:1.31–1.44) as compared to those untreated/treatment status unknown (SIR 1.16, 95% CI:1.13–1.19, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|